Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial.
Ismail NI, Nawawi KNM, Hsin DCC, Hao KW
Published in Helicobacter
Methodology
Randomized double-blind placebo-controlled trial: 2 weeks standard triple therapy then 4 weeks probiotic or placebo
Key Findings
Eradication 91.1% vs 68.9% by intention-to-treat (p = 0.007); probiotic group had greater reductions in indigestion, constipation, abdominal pain and total GSRS scores.
Conclusions
L. reuteri DSM 17648 as an adjunct improved eradication and gastrointestinal symptom scores.
Limitations
Small single-centre sample; unusually low eradication rate in the placebo arm may exaggerate the effect.
Supplements Studied
The eradication rate was higher in the probiotic group than in the placebo group, with a 22.2% difference in the intention-to-treat analysis (91.1% vs. 68.9%; p = 0.007).
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.